We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...

ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic ...

Backed by the venture portions of Eli Lily and Eisai, Excalipoint will look to progress the development of its six-strong TCE therapy pipeline.

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...

A first-in-class bispecific antibody achieved durable responses in a fourth of patients with advanced small cell lung cancer (SCLC) and disease control in more than half, a preliminary clinical trial ...

Peluntamig (PT217) targets DLL3 and CD47, receiving FDA orphan drug and fast track designations for SCLC and NEC. The SKYBRIDGE trial evaluates peluntamig's safety, tolerability, and efficacy in ...

IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images ...

DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...

Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.

Please provide your email address to receive an email when new articles are posted on . MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, ...

Molecular Partners announced positive IND-enabling data for MP0712 and preclinical findings for novel targeted Radio-DARPins at AACR 2025. Molecular Partners AG announced positive IND-enabling data ...